Hancock Jaffe Principal Investigator Dr Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium phoenixherald.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phoenixherald.com Daily Mail and Mail on Sunday newspapers.
Provided by Accesswire
Apr 23, 2021 4:40 PM UTC
IRVINE, CA / ACCESSWIRE / April 23, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine.
Patients in the first-in-human study demonstrated significant improvement in all study endpoints including an aggregate 54% improvement in reflux (the backwards flow of blood), a 56% improvement in disease manifestations, as measured by venous clinical severity scores ( rVCSS ), and a 76% improvement in pain, as measured on a visual
Hancock Jaffe Laboratories, Inc.: Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium April 23, 2021 /
Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLI s first-in-human VenoValve® study in Bogota, Colombia, presented one year data this past week at the Charing Cross International Symposium. The Charing Cross International Symposium is the longest-running vascular and endovascular global symposium in Europe and is attended by the world s leading experts in vascular and endovascular medicine.